Company profile: Kairos Therapeutics
1.1 - Company Overview
Company description
- Provider of a proprietary next-generation antibody-drug conjugate platform as a biopharmaceutical company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kairos Therapeutics
Acambis
HQ: United Kingdom
Website
- Description: Provider of vaccine research, development and manufacturing for the prevention and treatment of infectious diseases in Europe and North America, offering ACAM2000, a smallpox vaccine for emergency-use stockpiling, and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acambis company profile →
Orega Biotech
HQ: France
Website
- Description: Provider of immunotherapeutic monoclonal antibodies for cancer, including IPH5201, a humanized CD39 blocking antibody that inhibits adenosine production and is in Phase 2 trials for non-small cell lung cancer, and a novel preclinical human-mouse cross-reactive blocking antibody that improves the efficacy of anti-PD-1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orega Biotech company profile →
Adheron Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics that disrupt cell adhesion to treat a variety of diseases, based on pioneering work from Dr. Michael Brenner’s lab at Brigham and Women’s Hospital and Harvard Medical School, including work around Cadherin-11 (Cad-11), a cellular adhesive.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adheron Therapeutics company profile →
MacroGenics
HQ: United States
Website
- Description: Provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MacroGenics company profile →
ImmunoGenesis
HQ: United States
Website
- Description: Provider of immune therapies for tumor treatment, including IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor with cytotoxic effector function for immune-excluded tumors resistant to immunotherapies; IMGS-501, an antibody-conjugated STING agonist delivered via PD-L1/PD-L2 targeting to tumor sites; and IMGS-101, a hypoxia-reversal agent that reoxygenates the tumor microenvironment to enable T-cell access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGenesis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kairos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kairos Therapeutics
2.2 - Growth funds investing in similar companies to Kairos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kairos Therapeutics
4.2 - Public trading comparable groups for Kairos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →